Features of reproductive function realization in women with infertility and HIV infection in assisted reproductive technology programs
Objective. To evaluate the clinical and laboratory characteristics and efficiency of assisted reproductive technology (ART) programs in patients with HIV infection.Mityurina E.V., Perminova S.G., Selimova F.N., Kozyrina N.V., Abubakirov A.N.
Subjects and methods. A prospective case-control study was conducted in 94 patients who had consulted a doctor about ART programs. A study group included 38 women with HIV infection; a control group consisted of 56 HIV-seronegative patients. The study group underwent 74 in vitro fertilization (IVF) cycles, including 44 therapy cycles and 30 cryo ones. The control group had 59 and 30 cycles, respectively. The patients’ HIV infection status was assessed on the basis of the stage and phase of the disease, the level of viral load, CD3+,CD4+, and CD8+ lymphocytes, immunoreactive index, and the duration of antiretroviral treatment (ARVT).
Results. The duration of HIV infection was 10 years (median (interquartile range) 6-13 years); its subclinical stage 3 was dominant (68.4%). All the patients received combined ARVT. The median duration of drug use was 4 years (2-6.2 years). No blood viral load was detectable in 100% of cases. The patients in both groups were matched for age (median 34 and 32 years; p = 0.160) and infertility duration (5 and 5 years; p = 0.430). Tuboperitoneal (39.5 and 30.4%, p = 0.467) and combined (23.6 and 21.4%; p = 0.540) infertility factors were equally common in both groups. Anti-Müllerian hormone concentrations in HIV-infected women were significantly lower than those in HIV-seronegative patients (1.86 and 3.2 ng/ml; p = 0.024). Analysis of the stimulated cycle parameters revealed no significant difference in the starting and total doses of gonadotropins and in the duration of stimulation in both groups. Nevertheless, smaller numbers of oocytes (8.86±1.1 and 12.9±0.8; p = 0.001), mature oocytes (7.45±0.9 and 10.1±0.6; p = 0.003), zygotes (5.88±0.7 and 8.4±0.001; p = 0.001), cleavage-stage embryos (5.55±0.6 and 8.1±0.4; p = 0.001), as well as blastocysts (2.68±0.5 and 4.4±0.4; p = 0.009) were obtained from HIV-infected patients than from control subjects. Selective single embryo transfer was performed on day 3 or 5 of cultivation in both groups. HIV-infected patients were found to have lower incidence rates of biochemical and clinical pregnancy than HIV-seronegative women in both the therapy cycles of ART (17.2 and 44.2%, p = 0.015; 13.8% and 40.4%, p = 0,014) and cryo cycles (30 and 55.2%, p = 0.049; 20 and 53.6%; p = 0.008).
Conclusion. HIV-infected women receiving an IVF program were noted to have a higher frequency of cycle cancellation, fewer obtained oocytes, and the lowest pregnancy rate. Further investigations are needed to understand the specific effects of HIV and/or ARVT on an ovarian response, oocyte quality, and outcomes of ART programs.
Keywords
HIV
fertility
infertility
in vitro fertilization
Supplementary Materials
- Table 1. Immunological status of HIV-infected women
- Table 2. Clinical characteristics of HIV-infected women and controls
- Table 3. IVF results in seropositive patients and matched controls
References
1. Marques C., Guerreiro K., Soares S. Lights and shadows about the effectiveness of IVF in HIV infected women: A systematic review. Infect. Dis. Obstet. Gynecol. 2015; 2015: 517208.
2. Lampe M.A., Smith D.K., Anderson G.J., Edwards A.E., Nesheim S.R. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am. J. Obstet. Gynecol. 2011; 204(6): 488. e1-8.
3. Bujan L., Pasquier C. People living with HIV and procreation: 30 years of progress from prohibition to freedom? Hum. Reprod. 2016; 31(5): 918-25.
4. Savasi V., Mandia L., Laoreti A., Cetin I. Reproductive assistance in HIV serodiscordant couples. Hum. Reprod. Update. 2013; 19(2): 136-50.
5. Stora C., Epelboin S., Devouche E., Matheron S., Epelboin L., Yazbeck C. et al. Women infected with human immunodeficiency virus type 1 have poorer assisted reproduction outcomes: a case-control study. Fertil. Steril. 2016; 105(5): 1193-201.
6. Parsons T. Fertility rate of HIV-infected women is 37 percent less than that of healthy women. 2000. Available at: http://www.jhsph.edu/news/news-releases/2000/hiv-fertility.html
7. Shannon J., Benrubi G.I. Epidemiology of pelvic inflammatory disease at University Medical Centre, Jacksonville. J. Fla. Med. Assoc. 1991; 78(3): 158-61.
8. Englert Y., Lesage B., Van Vooren J.P., Liesnard C., Place I., Vannin A.S. et al. Medically assisted reproduction in the presence of chronic viral diseases. Hum. Reprod. Update. 2004; 10(2): 149-62.
9. Cejtin H.E., Kalinowski A., Bacchetti P., Taylor R.N., Watts D.H., Kim S. et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet. Gynecol. 2006; 108(6): 1423-31.
10. Coll O., Suy A., Figueras F., Vernaeve V., Martı´nez E., Mataro´ D. et al. Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART. .AIDS. 2006; 20(1): 121-3.
11. Martinet V., Manigart Y., Rozenberg S., Becker B., Gerard M., Delvigne A. Ovarian response to stimulation of HIV-positive patients during IVF treatment: a matched, controlled study. Hum. Reprod. 2006; 21(5): 1212-7.
12. Frodsham L., Cox A.D., Almeida A., Rozis G., Gilling-Smith C. In vitro fertilization in HIV positive women: potential mother and embryo viral transmission risk. Hum. Reprod. 2004; 19(Suppl. 1): abstr. 103.
13. Bagratee J.S. HIV/AIDS and reproduction: Background and indication for treatment. In: Kruger T.E., van der Spuy Z.M., Kempers R.D., eds. Advances in fertility studies and reproductive medicine. Cape Town: Juta Juta & Co Ltd; 2007: 414-9.
14. Ohl J., Partisani M., Wittemer C., Schmitt M.P., Cranz C., Stoll- Keller F. et al. Assisted reproduction techniques for HIV serodiscordant couples: 18 month experience. Hum. Reprod. 2003; 18(6): 1244-9.
15. Santulli P., Chopin N., Patrat C., Marcellin L., Wolf J.P., Chapron C. de Ziegler D. IVF-ICSI in HIV positive and sero-discordant couples: results of five-years of experience. Hum. Reprod. 2009; 24: Abstract Book 1: 342
16. Santulli P., Gayet V., Fauque P., Chopin N., Dulioust E., Wolf J.P. et al. HIV-positive patients undertaking ART have longer infertility histories than agematched control subjects. Fertil. Steril. 2011; 95(2): 507-12.
17. Savasi V., Antonazzo P., Personeni C. Pelvic inflammatory disease. N. Engl. J. Med. 2015; 372(21): 2039-48.
18. Harlow S.D., Schuman P., Cohen M., Ohmit S.E., Cu-Uvin S., Lin X., et al. Effect of HIV infection on menstrual cycle length. J. Acquir. Immune Defic. Syndr. 2000; 24(1): 68-75.
19. Massad L.S., Springer G., Jacobson L., Watts H., Anastos K., Korn A. et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS. 2004; 189(2): 281-6.
20. Nurudeen S.K., Grossman L.S., Bourne L., Guarnaccia M.M., Sauer M.V., Douglas N.C. Reproductive outcomes of HIV seropositive women treated by assisted reproduction. J. Womens Health. 2013; 22(3): 243-9.
21. Ohl J., Partisani M., Demangeat C., Binder-Foucard F., Nisand I., Lang G.M. Alterations of ovarian reserve tests in Human Immunodeficiency Virus (HIV)-infected women. Gynecol. Obstet. Fertil. 2010; 38(5): 313-7.
22. Manigart Y., Rozenberg S., Barlow P., Gerard M., Bertrand E., Delvigne A. ART outcome in HIV-infected patients. Hum. Reprod. 2006; 21(11): 2935-40.
23. Douglas N.C., Wang J.G., Yu B., Gaddipati S., Guarnaccia M., Sauer M.V. A systematic, multidisciplinary approach to address the reproductive needs of HIV-seropositive women. Reprod. BioMed. Online. 2009; 19(2): 257-63.
24. Prisant N., Tubiana R., Lefebvre G., Lebray P., Marcelin A.G., Thibault V. et al. HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. Fertil. Steril. 2010; 93(3):1020-3.
25. Terriou P., Auquier P., Chabert-Orsini V., Chinchole J.M., Cravello L., Giorgetti C. et al. Outcome of ICSI in HIV-1-infected women. Hum. Reprod. 2005; 20(10): 2838-43.
26. Краснопольская К.В., Назаренко Т.А., Гафуров Ю.Т. Место вспомогательных репродуктивных технологий в реализации репродуктивной функции у ВИЧ-инфицированных лиц. Российский вестник акушера-гинеколога. 2013; 13(3): 47-55. [Krasnopolskaya K.V., Nazarenko T.A., Gafurov Yu.T. Place of assisted reproductive technologies in the realization of reproductive function in HIV-infected individuals. Rossiyskiy vestnik akushera-ginekologa. 2013; 13(3): 47-55. (in Russian)]
27. Назаренко Т.А., Краснопольская К.В., Исакова К.М. Программа ЭКО у ВИЧ-инфицированных пациентов (отбор больных и особенности проведения). Проблемы репродукции. 2016; 22(4): 60-5. [Nazarenko T.A., Krasnopolskaya K.V., Isakova K.M. The IVF program in HIV-infected patients (selection of patients and peculiarities of conduction). Problemyi reproduktsii. 2016; 22(4): 60-5.
28. Reynier P., May-Panloup P., Chrétien M.F., Morgan C.J., Jean M., Savagner F. et al. Mitochondrial DNA content affects the fertilizability of human oocytes. Mol. Hum. Reprod. 2001; 7(5): 425-9.
Received 02.06.2017
Accepted 23.06.2017
About the Authors
Mityurina Elena V., PhD, doctor of the 1st Gynecologic Department, Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia.117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79647967465. E-mail: mity-elena@yandex.ru
Perminova Svetlana G., MD, leading researcher of 1st gynecological department, Research Center of Obstetrics, Gynecology and Perinatology,
Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79162021687. E-mail: perisvet@list.ru
Selimova Fatima N., post-graduate student of the 1st gynecological department, Research Center of Obstetrics, Gynecology and Perinatology,
Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79268887755. E-mail: doc.fselimova@mail.ru
Kozyrina Nadezhda V., PhD, researcher of the Central Research Institute of Epidemiology of Rospotrebnadzor.
111123, Russia, Moscow, Novogireevskaya str. 3а. Tel.: +79167151018. E-mail: nad-kozyrina@yandex.ru/
Abubakirov Aydar N., Ph.D., the head of the 1st Gynecologic Department, Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia.
117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79165524991. E-mail: a_abubakirov@oparina4.ru
For citations: Mityurina E.V., Perminova S.G., Selimova F.N., Kozyrina N.V., Abubakirov A.N. Features of reproductive function realization in women with infertility and HIV infection in assisted reproductive technology programs.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (10): 70-7. (in Russian)
https://dx.doi.org/10.18565/aig.2017.10.70-77
Similar Articles
